A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in NSCLC patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN)
Non Small Cell Lung Cancer
DRUG: Efgbemalenograstim alfa
The incidence rate of Grade ≥3 ANC reduction, The incidence rate of Grade ≥3 ANC reduction during the first chemotherapy cycle for two groups of participants receiving primary and secondary prophylaxis with Efgbemalenograstim alfa in the first treatment cycle., Up to a year and a half after starting chemotherapy
The incidence rate of FN, The incidence rate of febrile neutropenia (FN) for each cycle, Up to a year and a half after starting chemotherapy|The incidence rate of Grade ≥3 ANC reduction, The incidence rate of Grade ≥3 ANC reduction during chemotherapy cycles 2-4/6, Up to a year and a half after starting chemotherapy|Adverse Events, Including adverse events/serious adverse events and their incidence rates, Up to a year and a half after starting chemotherapy
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in NSCLC patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN)